The U.S. Government has filed a lawsuit accusing Gilead Sciences of violating patents owned by the U.S. Department of Health and Human Services related to Truvada, Gileads HIV prevention drug. Gibbs Law Group has launched a Gilead Sciences Investor Lawsuit investigation on behalf of those who invested in Gilead Sciences (NASDAQ: GILD).
To speak with an attorney regarding this lawsuit investigation, click here or call (888) 410-2925.
On November 6, 2019, the U.S. Department of Health and Human Services filed a lawsuit against Gilead Sciences, accusing the company of infringing on government patents on Truvada, and the concept of PrEP, or pre-exposure prophylaxis, which can prevent H.I.V. with a daily pill.
The lawsuit specifically alleges that CDC researchers began studying the preventive use of HIV treatment drugs like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet as early as 1998, before Gilead sought a patent.
In a statement about the patent lawsuit, Alex Azar II, the secretary of the Department of Health and Human Services stated:
Gilead must respect the U.S. patent system, the groundbreaking work by researchers with the Centers for Disease Control and Prevention, and the substantial taxpayer contributions to the development of these drugs.
What Should Gilead Sciences Investors Do?
If you invested in Gilead Sciences, you may have legal claims. Visit our website or contact our securities team directly at (888) 410-2925 to discuss your possible legal options. Our investigation concerns whether Gilead Sciences and certain of its officers and/or directors have violated federal securities laws.
About Gibbs Law Group
Gibbs Law Group represents individual and institutional investors throughout the country in securities litigation to correct abusive corporate governance practices, breaches of fiduciary duty, and proxy violations. The firm has recovered over a billion dollars for its clients against some of the worlds largest corporations, and our attorneys have received numerous honors for their work, including Best Lawyers in America, Top Plaintiff Lawyers in California, California Lawyer Attorney of the Year, Top Class Action Attorneys Under 40, Consumer Protection MVP, and Top Cybersecurity/ Privacy Attorneys Under 40.
This press release may constitute Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
CONTACT: EILEEN EPSTEIN
EMAIL: [email protected]